Contrast Agent Market Leading Players and Business Intelligence
According to the new market research report Contrast Agent Market is projected to USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911
The
growth in this market can be attributed to the rising prevalence of
chronic diseases, growing approvals of contrast agents, rising volume of
CT and MRI examinations performed, growing number of diagnostic centers
and hospitals, and availability of reimbursement. Emerging markets in
Asian countries are expected to offer strong growth opportunities for
players in the market. In contrast, the high cost and inaccessibility of
advanced therapeutics may restrict market growth to a certain extent.
The contrast media/ contrast agents market is segmented based on type,
modality, route of administration, indication, application, end user,
and region.
The global contrast media market is consolidated. The
prominent players operating in this market include GE Healthcare (US),
Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), J.B.
Chemicals and Pharmaceuticals Ltd. (India), Lantheus Medical Imaging,
Inc. (US), Unijules Life Sciences Ltd. (India), SANOCHEMIA Pharmazeutika
GmbH (Austria), Taejoon Pharm (South Korea), Trivitron Healthcare Pvt.
Ltd. (India), Nano Therapeutics Pvt. Ltd. (India), and YZJ Group
(China).
GE Healthcare (US) is the leading player in the contrast
media/ contrast agents market in 2020. The company serves customers in
more than 170 countries and has a strong distribution network globally
across the Americas, Europe, the Pacific Basin, and the Middle East
& Africa. GE Healthcare’s pharmaceutical segment has a strong
foothold in the US, accounting for 42% of its total revenues.
Bracco
Imaging SPA (Italy) accounted for the high share of the contrast media/
contrast agents market in 2020. The company has a broad product
portfolio in the X-ray and CT contrast media segment. The company
markets its contrast media products in over 100 countries directly or
indirectly. It generates 89% of revenue through international sales.
Guerbet
(France) held the third position in the contrast media/ contrast agents
market in 2020. The majority of its revenue is generated from the
European region (45%). The company focuses on expanding its geographical
base by entering into various distribution agreements globally. For
instance, the company has planned to establish its distribution platform
in Japan (the world’s second-largest contrast media market for MR and
CT & cath labs) by 2023 as part of its Strategic Plan Gear 2023.
Bayer
AG (Germany) held the third position in the contrast media/ contrast
agents market in 2020. The company has a strong portfolio of MRI
contrast agents and the upper hand in the MRI contrast market. The
company has a broad product portfolio in the MRI contrast media segment,
with Gadovist bringing the majority of sales for Bayer.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911
The
Contrast Agent Market is segmented into five major regions, namely,
North America, Europe, Asia Pacific, Latin America and the Middle East
& Africa (MEA). North America was the largest regional market in
2020. The large share of the North American market can be attributed to
presence of major players in the region, high prevalence of chronic
disorders, growing geriatric population, and the increasing adoption of
minimally invasive procedures.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
You really take your time in writing this article and they are clearly detailed as the articles on the site myeloid cells Please check the report
ReplyDeletemyeloid therapies